Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxorubicin hydrochloride
Drug ID BADD_D00724
Description Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Indications and Usage Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Marketing Status approved; investigational
ATC Code L01DB01
DrugBank ID DB00997
KEGG ID D01275
MeSH ID D004317
PubChem ID 443939
TTD Drug ID D07VLY
NDC Product Code 0069-3032; 0069-4015; 0069-4037; 0143-9091; 45963-733; 68001-493; 70710-1530; 17337-0260; 0069-3030; 58623-0119; 0143-9089; 0143-9371; 43598-283; 0338-0063; 62756-826; 62756-827; 63323-101; 72603-103; 56161-101; 0069-4026; 0143-9086; 63629-9531; 70121-1219; 0338-0067; 63629-9530; 70710-1531; 0574-0930; 12064-019; 77391-001; 47335-049; 68001-492; 70860-208; 72603-200; 0143-9275; 43598-683; 49315-008; 68001-345; 68083-250; 0574-0931; 53183-7000; 0069-3033; 0143-9372; 0143-9546; 0143-9547; 43598-541; 63323-883; 68083-248; 58623-0029; 16714-001; 0143-9093; 0143-9370; 0069-4004; 16714-742; 0143-9085; 0143-9087; 0143-9090; 0143-9548; 0069-3031; 0069-3034; 16714-856; 0143-9084; 0143-9369; 43598-682; 47335-050; 49315-009; 67457-436; 68083-249; 0143-9088; 0143-9092; 0143-9277; 0143-9549
UNII 82F2G7BL4E
Synonyms Doxorubicin | Farmiblastina | Ribodoxo | Rubex | Adriamycin | Adriblastin | Adriblastine | Adriblastina | Adriablastine | Adriablastin | Adrimedac | DOXO-cell | DOXO cell | Urokit Doxo-cell | Urokit Doxo cell | Doxolem | Doxorubicin Hexal | Doxorubicin Hydrochloride | Hydrochloride, Doxorubicin | Doxorubicin NC | Doxorubicina Ferrer Farm | Doxorubicina Funk | Doxorubicina Tedec | Doxorubicine Baxter | Doxotec | Myocet | Onkodox
Chemical Information
Molecular Formula C27H29NO11.ClH
CAS Registry Number 25316-40-9
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O .Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acne23.02.01.001--Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.001--Not Available
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Bundle branch block02.03.01.009--Not Available
Cardiac arrest02.03.04.001--
Cardiomyopathy02.04.01.001--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Cough22.02.03.001--
Cryptococcosis11.03.04.001--Not Available
Dehydration14.05.05.001--
Depression19.15.01.001--
Dermatitis bullous23.03.01.002--
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry eye06.08.02.001--
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Ecchymosis01.01.03.001; 24.07.06.002; 23.06.01.001--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene